Biology of Blood and Marrow Transplantation
Volume 12, Issue 12 , Pages 1343-1349 , December 2006

Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation

  • Navin Wadehra

      Affiliations

    • Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio
    • ,
  • Sherif Farag

      Affiliations

    • Department of Medicine, Division of Hematology and Oncology, Indiana University, Indianapolis, Indiana
    • Corresponding Author InformationCorrespondence and reprint requests: Sherif Farag, MD, PhD, Department of Medicine, Division of Hematology and Oncology, Indiana University, 635 Barnhill Drive, Indianapolis, IN 46202.
    • ,
  • Brian Bolwell

      Affiliations

    • Hematologic Oncology and Blood Disorders, The Cleveland Clinic, Cleveland, Ohio
    • ,
  • Patrick Elder

      Affiliations

    • Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio
    • ,
  • Sam Penza

      Affiliations

    • Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio
    • ,
  • Matt Kalaycio

      Affiliations

    • Hematologic Oncology and Blood Disorders, The Cleveland Clinic, Cleveland, Ohio
    • ,
  • Belinda Avalos

      Affiliations

    • Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio
    • ,
  • Brad Pohlman

      Affiliations

    • Hematologic Oncology and Blood Disorders, The Cleveland Clinic, Cleveland, Ohio
    • ,
  • Guido Marcucci

      Affiliations

    • Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio
    • ,
  • Ronald Sobecks

      Affiliations

    • Hematologic Oncology and Blood Disorders, The Cleveland Clinic, Cleveland, Ohio
    • ,
  • Thomas Lin

      Affiliations

    • Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio
    • ,
  • Steven Andrèsen

      Affiliations

    • Hematologic Oncology and Blood Disorders, The Cleveland Clinic, Cleveland, Ohio
    • ,
  • Edward Copelan

      Affiliations

    • Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio

Received 17 April 2006 ,Accepted 25 August 2006.

References 

  1. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478
  2. Klimo P, Connors JM. An update on the Vancouver experience in the management of advanced Hodgkin’s disease treated with MOPP/ABV hybrid program. Semin Hematol. 1994;25:34
  3. De Vita VT, Hubbard SM. Hodgkin’s disease. N Engl J Med. 1993;328:560–565
  4. Linch DC, Winfield D, Goldstone AH, et al. Dose identification with autologous bone marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomized trial. Lancet. 1993;341:1051–1054
  5. Schmitz N, Glass B, Dreger P, et al. High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin’s disease. Ann Hematol. 1993;66:251–256
  6. Lancet JE, Rapoport AP, Brasacchio R, et al. Auto-transplantation for relapsed or refractory Hodgkin’s disease: long term follow-up and analysis of prognostic factors. Bone Marrow Transplant. 1998;22:265–271
  7. Lazarus HM, Rowlings PA, Zhang MJ, et al. Autotransplants for Hodgkin’s disease in patients never achieving remission: a report from Autologous Blood and Marrow Registry. J Clin Oncol. 1999;17:534–545
  8. Sweetenham JW, Carella AM, Taghipour G, et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin’s disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. J Clin Oncol. 1999;17:3101–3109
  9. Yuen AR, Rosenberg SA, Hoppe RT, Halpern JD, Horning SJ. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin’s disease. Blood. 1997;89:814–822
  10. Nademanee A, O’Donnel MR, Snyder DS, et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin’s disease: results in 85 patients with analysis of prognostic factors. Blood. 1995;85:1381–1390
  11. Horning SJ, Chao NJ, Negrin RS, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin’s disease: analysis of the Stanford University results and prognostic indices. Blood. 1997;89:801–813
  12. Gutierrez-Delgado F, Holmberg L, Hooper H. Autologous stem cell transplantation for Hodgkin’s disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen. Bone Marrow Transplant. 2003;32:279–285
  13. Kliss TL, Panzarella T, Messner HA, et al. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2003;31:73–78
  14. Avalos BR, Klein JL, Kapoor PJ, Tutschka PJ, Klein JP, Copeland EA. Preparation for marrow transplantation in Hodgkin’s and non-Hodgkin’s lymphoma using Bu/CY. Bone Marrow Transplant. 1993;12:133–138
  15. Weaver CH, Schwartzberg L, Rhinehart S, et al. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin’s lymphoma. Bone Marrow Transplant. 1998;21:383–389
  16. Copelan EA, Kapoor N, Gibbins B, Tutschka PJ. Allogeneic marrow transplantation for non-Hodgkin’s lymphoma. Bone Marrow Transplant. 1990;5:47–50
  17. Kroger N, Zabelina T, Sonnenberg S, et al. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia. Bone Marrow Transplant. 2000;26:711–716
  18. Zander AR, Berger C, Kroger N, et al. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. Clin Cancer Res. 1997;3:2671–2675
  19. Kroger N, Hoffknecht M, Hanel M, et al. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy. Bone Marrow Transplant. 1998;21:1171–1175
  20. Copelan EA, Penza SL, Pohlman B, et al. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2000;25:1243–1248
  21. Hanel M, Kroger N, Sonnenberg S, et al. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann Hematol. 2002;81:96–102
  22. Litzow M, Perez W, Klein JP, et al. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol. 2002;119:1115–1124
  23. Thomas ED, Storb R. Technique for human marrow grafting. Blood. 1970;36:507–515
  24. Bensinger W, Singer J, Appelbaum F, et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte colony stimulating factor. Blood. 1993;81:3158–3163
  25. Rowley SD, Bensinger W, Goolet TA, Buckner CD. The effect of cell concentration on bone marrow and peripheral blood stem cell cryopreservation. Blood. 1994;83:2731–2736
  26. Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin’s disease. Cancer Res. 1966;26:1063–1081
  27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  28. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187–220
  29. Anderson JE, Litzow MR, Appelbaum FR, et al. Allogeneic, syngeneic and autologous marrow transplantation for Hodgkin’s disease: the 21 year Seattle experience. J Clin Oncol. 1993;11:2342–2350
  30. Deej HJ. Delayed complications after bone marrow transplantation. In:  Forman SJ,  Blum KG,  Thomas ED editor. Bone Marrow Transplantation. Boston, MA: Scientific Publications; 1994;p. 538–544
  31. Sureda A, Arranz R, Iriondo A, et al. Autologous stem-cell transplantation for Hodgkin’s disease: results and prognostic factors in 494 patients from Grupo Espanol de Linformas/Transplante Autologo de Medula Osease Spanish Cooperative Group. J Clin Oncol. 2001;19:1395–1404
  32. Jagannath S, Dicke KA, Armitage JO, et al. High-dose cyclophosphamide, carmustine and etoposide and autologous bone marrow transplantation for relapsed Hodgkin’s disease. Ann Intern Med. 1986;104:163–168
  33. Lavoie JC, Connors JM, Phillips GL, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma: long-term outcome in the first 100 patients in Vancouver. Blood. 2005;106:1473–1478
  34. Chopra R, McMillan AK, Linch DC, et al. The place of high dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin’s disease (A single center 8 year study of 155 patients). Blood. 1993;81:1137–1145
  35. Martin A, Fernandez-Jimenez MC, Calallero M, et al. Long-term follow-up in patients treated with mini-BEAM as a salvage therapy for relapsed or refractory Hodgkin’s disease. Br J Haematol. 2001;113:171;2001
  36. Jones RJ, Piantadosi S, Mann R, et al. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol. 1990;8:527–537
  37. Schiffman K, Buckner C, Maziarz R, et al. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin’s disease. Biol Blood Marrow Transplant. 1997;3:261–266
  38. Farag SS, Bolwell BJ, Elder PJ, et al. High-dose busulfan, cyclophosphamide, and etoposide do not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia. Bone Marrow Transplant. 2005;35:653–661
  39. Czyz J, Dziadziuszko R, Knopinska-Postuszuy W, et al. Outcome and prognostic factors in advanced Hodgkin’s disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients. Ann Oncol. 2004;15:1222–1230
  40. Reece DE, Barnett MJ, Shepherd JD, et al. High-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16) with or without cisplatin and autologous transplantation for patients with Hodgkin’s disease who fail to enter a complete remission after combination chemotherapy. Blood. 1995;86:451–456
  41. Crump M, Smith AM, Brandwein J, et al. High dose etoposide and melphalan and autologous bone marrow transplantation for patients with advanced Hodgkin’s disease: importance of disease status at transplant. J Clin Oncol. 1993;11:711
  42. Kashyap A, Wingard J, Cagnoni P, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant. 2002;8:493–500
  43. Crilley P, Topolsky D, Styler M, et al. Extramedullary toxicity of a conditioning regimen containing busulfan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15:361–365
  44. Siddiqui MA, Wellington K. Palifermin: in myelotoxic therapy-induced oral mucositis. Drugs. 2005;65:2139–2146
  45. Moskowitz C, Nimer S, Zelenetz A, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2006;97:616–623
  46. Brice P, Bouabdallah R, Moreau P, et al. Prognostic factors for survival after high dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from French registry. Bone Marrow Transplant. 1997;20:21–26
  47. Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol. 2005;16:625–633
  48. Copelan EA, Deeg HJ. Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation. Blood. 1992;80:1658
  49. Friedberg JW, Neuberg D, Stone RM, et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17:3128–3135
  50. Anderson JE, Gooley TA, Schoch G, et al. Stem cell transplantation for secondary acute myeloid leukemia: an evaluation of transplantation as initial therapy or following induction chemotherapy. Blood. 1997;89:2578–2585
  51. Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood. 2003;5:2015–2023
  52. Bolwell B, Kalaycio M, Sobecks R, et al. Secondary malignancy after autologous stem cell transplantation (ABMT) for non-Hodgkin’s lymphoma and Hodgkin’s disease using a busulfan containing preparative regimen. Blood. 2002;100(11):418a
  53. Curtis R, Rowlings P, Deeg H, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336:897–904
  54. Miller JS, Arthur DC, Litz CE, Neglia JP, Miller WJ, Weisdorf DJ. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood. 1994;83:3780–3786
  55. Stone RM, Neuberg D, Soiffer R, et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin’s lymphoma. J Clin Oncol. 1994;12:2535–2542
  56. Darrington DL, Vose JM, Anderson JR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol. 1994;12:2527–2534
  57. Andre M, Henry-Amar M, Blaise D, et al. Treatment-related deaths and secondary cancer risk after autologous stem cell transplantation for Hodgkin’s disease. Blood. 1998;92:1933–1940

PII: S1083-8791(06)00601-X

doi: 10.1016/j.bbmt.2006.08.039

Biology of Blood and Marrow Transplantation
Volume 12, Issue 12 , Pages 1343-1349 , December 2006

Article Tools

* Image Usage & Resolution